Advertisement

Neue Arzneimittel

  • Uwe Fricke
  • Ulrich Schwabe

Zusammenfassung

Im Jahre 2003 sind deutlich weniger Arzneimittel mit neuen Wirkstoffen (17) als im Vorjahr (28 neue Wirkstoffe) in Deutschland eingeführt worden, Über-wiegend handelt es sich urn therapeutische Innovationen (7 Wirkstoffe) oder Wirkstoffe mit verbesserten Eigenschaften (5 Wirkstoffe). Fast die Hälfte dieser neuen Arzneimittel verursacht bei der erforderlichen Dauertherapie Kosten von 3.000 bis 650.000 € pro Jahr. Nicht empfehlenswert ist das Anatogpraparat Escitalopram (Cipralex),da inzwischen deutlich preiswertere Citalopramgenerika verfügbar sind. Die Neueinführungen der letzten zehn Jahre zeigen wiederum ein überproportionales Umsatzwachstum (21,5%) und haben dadurch ihren Anteil am Gesamtumsatz des Arzneimittelmarkts weiter erhöht (30,0%, Vorjahr 27,7 %).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrams LS, Skee DM, Wong FA, Anderson NJ, Leese PT (2001): Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches. J Clin Pharmacol 41:1232–1237.PubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen Apotheker (2002): Rote-Hand-Brief: Parecoxib (Dynastat®). Pharm Ztg 147:4188.Google Scholar
  3. Bang LM, Scott LJ (2003): Emtricitabine. Drugs 63:2413–2424.PubMedCrossRefGoogle Scholar
  4. Black DM., Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF et al. for the PaTH Study Investigators (2003): The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215.PubMedCrossRefGoogle Scholar
  5. Body J-J, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A et al. (2002): A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–349] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535.PubMedCrossRefGoogle Scholar
  6. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. (2002): Efficacy and safety of tadalafil for the treatment of erectile dysfuntion: results of integrated analyses. J Urol 168:1332–1336.PubMedCrossRefGoogle Scholar
  7. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G et al. (2004): Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144:112–120.PubMedCrossRefGoogle Scholar
  8. CLASS Advisory Committee (2001): Celecoxib. Briefing Document. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677bl_01_Searle.pdf.Google Scholar
  9. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O’Brien M, Schellens JH et al. (2001): Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 37: 835–842.PubMedCrossRefGoogle Scholar
  10. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebícek M et al. (2000): Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355:1481–1485.PubMedCrossRefGoogle Scholar
  11. De Witt R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M et al. (2003): Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21:4105–4111.CrossRefGoogle Scholar
  12. Enserink M (1999): Can the placebo be the cure? Science 284: 238–240.PubMedCrossRefGoogle Scholar
  13. European Agency for the Evaluation of Medicinal Products (EMEA) (2002a): Inductos. European Public Assessment Report (EPAR), CPMP/3188/02, 9 September 2002.Google Scholar
  14. European Agency for the Evaluation of Medicinal Products (EMEA) (2002b): Zavesca. European Public Assessment Report (EPAR), CPMP/3795/02, 20. November 2002.Google Scholar
  15. European Agency for the Evaluation of Medicinal Products (EMEA) (2002c): Evra. European Public Assessment Report (EPAR), CPMP/2748/02,22. August 2002.Google Scholar
  16. European Agency for the Evaluation of Medicinal Products (EMEA) (2003a): Emtriva. European Public Assessment Report (EPAR), CPMP/4014/03,24 Oktober 2003.Google Scholar
  17. European Agency for the Evaluation of Medicinal Products (EMEA) (2003b): Fuzeon. European Public Assessment Report (EPAR), CPMP/1695/03,27 Mai 2003.Google Scholar
  18. Fricke U (2000): Arzneimittelinnovationen — Neue Wirkstoffe: 1978–1999. Eine Bestandsaufnahme. In: Klauber J, Schröder H, Selke GW (Hrsg): Innovation im Arzneimittelmarkt, Springer-Verlag, Berlin-Heidelberg-New York, pp. 85–97.CrossRefGoogle Scholar
  19. Fricke U (2003): Neue Arzneimittel — Ein Überblick. Therapiesymposium 2003. Arzneimittelkommission der deutschen Ärzteschaft, Bad Nauheim.Google Scholar
  20. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al. (2003): Adalimumab, a fully human anti-tumor necrosis factor-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30: 2563–2571.PubMedGoogle Scholar
  21. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R et al for the BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group (2002): Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. Bone Joint Surg Am 84-A: 2123–2134.Google Scholar
  22. Gräfe KA (2003): Escitalopram wirksamer als das Racemat. Pharm Ztg 148: 4116–4117.Google Scholar
  23. Gresser U, Gleiter CH (2002): Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil — review of the literature. Eur J Med Res 7:435–446.PubMedGoogle Scholar
  24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, Rizzetto M et al. for the Adefovir Dipivoxil 438 Study Group (2003): Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800–807.PubMedCrossRefGoogle Scholar
  25. Heitner R, Elstein D, Aerts J, Weely S, Zimran A (2002): Low-dose N-butyldeoxynoji-rimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 28:127–133.PubMedCrossRefGoogle Scholar
  26. Hellstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley CM, Watkins VS (2003): Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 170: 887–891.PubMedCrossRefGoogle Scholar
  27. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000): Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85: 2958–2961.PubMedCrossRefGoogle Scholar
  28. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al. for the Aprepitant Porotocol 052 Study Group (2003): The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose Cisplatin. J Clin Oncol 21:4112–4119.PubMedCrossRefGoogle Scholar
  29. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH (2003): Comparison of the efficacy of the tumour necrosis factor a blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62(Suppl II): ii13–ii16.PubMedGoogle Scholar
  30. Holmes FA, O’Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M et al. (2002): Blinded, randomized, multicenter study to evaluate single administration peg-filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20: 727–731.PubMedCrossRefGoogle Scholar
  31. IMS World Review (2004): 2002 World Pharma Sales Growth: Lipitor leads the way. http://www.ims-global.com. 18. März 2004.Google Scholar
  32. Josefson D (2003): US advertising campaign begins for alternative to sildenafil. Brit Med J 327:468.PubMedCrossRefGoogle Scholar
  33. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M et al. (2001): Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182–188.PubMedCrossRefGoogle Scholar
  34. Keating GM, Scott LJ (2003): Vardenafil. Drugs 63:2673–2703.PubMedCrossRefGoogle Scholar
  35. Kris MG (2003): Why do we need another antiemetic? Just ask. J Clin Oncol 21: 4077–4080.CrossRefGoogle Scholar
  36. Kuijpers G, Schneider B, Stadel B, Colman E (2002): Recombinant human parathyroid hormone. Brit Med J 324:1218.PubMedCrossRefGoogle Scholar
  37. Lalezari JP, Henry K, O’Hearn M, Montaner JSG, Piliero PJ, Trottier B et al. for the TORO 1 Study Group (2003): Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. J Engl J Med 348: 2175–2185.CrossRefGoogle Scholar
  38. Lazzarin A, Clotet B, Cooper D, Reynes J, Keikawus A, Nelson M et al. for the TORO 2 Study Group (2003): Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348: 2186–2195.PubMedCrossRefGoogle Scholar
  39. Mamdani M, Juurlink DN, Kopp A, Austin PC, Laupacis A (2004): Gastrointestinal bleeding after introduction of COX 2 inhibitors: ecological study. BMJ, 328: 1415–1416.PubMedCrossRefGoogle Scholar
  40. Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W, Shiffman ML et al. For the Adefovir Dipivoxil 437 Study Group (2003): Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348: 808–816.PubMedCrossRefGoogle Scholar
  41. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe L et al. for the Finasteride Long-Term Efficacy and Safety Study Group (1998): The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557–563.PubMedCrossRefGoogle Scholar
  42. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al. for the L-754,030 Antiemetic Trials Group (1999): Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:190–195.PubMedCrossRefGoogle Scholar
  43. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y et al. (2001): Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.PubMedCrossRefGoogle Scholar
  44. Norman RW, Coakes KE, Wright AS, Rittmaster RS (1993): Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 150:1736–1739.PubMedGoogle Scholar
  45. Ormrod D, Wellington K, Wagstaff AJ (2002): Valdecoxib. Drugs 62:2059–2071.PubMedCrossRefGoogle Scholar
  46. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC et al. for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group and Ischemia Research and Education Foundation (IREF) Investigators (2003): Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481–1492.PubMedCrossRefGoogle Scholar
  47. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R et al. (2004): Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91–101.PubMedCrossRefGoogle Scholar
  48. Reeve J (2002): Recombinant human parathyroid hormone. Brit Med J 324:435–436.PubMedCrossRefGoogle Scholar
  49. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli JM et al. (1976): Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1:1035–1038.PubMedCrossRefGoogle Scholar
  50. Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D et al. (2001): Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharm Exp Ther 296: 558–566.Google Scholar
  51. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G for the ARIA3001 ARIA3002 and ARIA 3003 Study Investigators (2002): Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology a60:434–441.CrossRefGoogle Scholar
  52. Stedman CAM, Barclay ML (2000): Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14: 963–978.PubMedCrossRefGoogle Scholar
  53. Steinbrook R (2003): HIV infection — a new drug and new costs. N Engl J Med 348: 2171–2172.PubMedCrossRefGoogle Scholar
  54. Svensson S, Mansfield PR (2004): Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73:10–16.PubMedCrossRefGoogle Scholar
  55. Tashima KR, Carpenter CCJ (2003): Fusion inhibition — a major but costly step forward in the treatment of HIV-1. N Engl J Med 348:2249–2250.PubMedCrossRefGoogle Scholar
  56. Taylor D (2003): Fewer new drugs from the pharmaceutical industry. Brit Med J 326: 408–409.PubMedCrossRefGoogle Scholar
  57. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ et al. (2000): Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171–1177.PubMedCrossRefGoogle Scholar
  58. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al. (2001): Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754–1759.PubMedCrossRefGoogle Scholar
  59. WHO Collaborating Centre for Drug Statistics Methodology (2004): ATC-Index mit DDD. Oslo, Norwegen.Google Scholar
  60. Wyllie MG (2003): The phosphodiesterase inhibitor ‘war’. Br J Urol 91: 573–574.CrossRefGoogle Scholar
  61. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fischer AC, Creasy GW (2002): Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ trans-dermal system: the analysis of pooled data. Fertil Steril 77(Suppl 2): S13–S18.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Uwe Fricke
    • 1
  • Ulrich Schwabe
    • 2
  1. 1.Institut für Pharmakologie der Universität zu KölnKöln
  2. 2.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations